Going anti-Viral
Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I’m Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.
Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.
Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a clinical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.
Going anti-Viral
Navigating HIV Care with GLP-1 Receptor Agonists – Dr Darcy Wooten
In episode 55 of Going anti-Viral, Dr Darcy Wooten joins host Dr Michael Saag to discuss navigating HIV care with glucagon-like peptide-1 (GLP-1) receptor agonists. Dr Wooten is a Professor of Medicine in the Division of Infectious Diseases at Washington University in St. Louis. Her clinical interests are HIV primary care, HIV prevention, sexually transmitted infections, and general infectious diseases. Dr Wooten is also a national leader in medical education. Dr Wooten provides an overview of GLP-1 receptor agonists including their history of use for the treatment of diabetes and more recent use for treatment of weight loss. Dr Saag and Dr Wooten discuss the challenges that patients have in getting insurance coverage for GLP-1 receptor agonists and review the 2 most common drugs that are used as treatment, tirzepatide and semaglutide. They discuss the patient experience with the injectable medication and review the possibility of oral versions of the medications in the future. Finally, Dr Saag and Dr Wooten discuss the long-term management of GLP-1 receptor agonists as a part of overall primary care for patients with HIV.
0:00 – Introduction
1:11 – Overview of GLP-1 receptor agonists
3:46 – How GLP-1 receptor agonists became used for weight management and patient eligibility criteria
6:14 – Challenges of insurance coverage for GLP-1 receptor agonists
8:32 – Differences between theGLP-1 receptor agonists tirzepatide and semaglutide and other benefits of the medications beyond weight loss
12:04 – Patient experience with the injectable formulations and possible adverse effects of use
14:36 – Long-term use of GLP-1 receptor agonists and possibility of oral versions of these drugs
17:36 – Managing GLP-1 receptor agonists as a part of primary care for patients with HIV including treatment of some substance use disorders
20:22 – Predictions for future management of GLP-1 receptor agonists and Dr Wooten’s hope for more research into incorporating lifestyle modifications into patient care
__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.
Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...